We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.125 | 10.20% | 1.35 | 1.30 | 1.40 | 1.35 | 1.20 | 1.23 | 8,345,835 | 16:20:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.26 | 10.47M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/1/2021 22:26 | This guy Tim . Is living in a dream. He has his head so much up,, His own Ass. Can not see the wood for the trees. By the time he gets to market he be collecting his pension. Lol .. He needs to go back to school To the do his business studies . As he has not got a clue .. | goforgold1 | |
28/1/2021 21:25 | Why is he even mentioning specific prices? If he'd just do his job properly the share price will take care if itself. | lako42 | |
28/1/2021 16:29 | Just listened to Tim on VOX and it was the most fluent I’ve heard him but I would just like to comment on one remark which I found Flabbergasting. He is clearly of the opinion the share fall as been overdone but he suggests that on a USA licensing deal the share price should get back to £1.20 range if not a little more is he not aware that 12 months ago we were trading at £1.70 in anticipation of a deal which you would of imagined would have driven the valuation above £2 it was just a crazy remark | best1467 | |
28/1/2021 13:13 | We all know TW isnt the world's best presenter but his performance on the podcast was fine. Definitely not "poor". | t0pgrader | |
28/1/2021 11:04 | I guess you prbably know this... generally anything he/they have done from an IR perspective will be found on hxxps://www.shieldth | innittowinit | |
28/1/2021 09:06 | do you have a link to the podcast please? | t0pgrader | |
28/1/2021 02:01 | Poor podcast with Mr waites. | letmepass | |
27/1/2021 22:54 | Told you all 45p | goforgold1 | |
27/1/2021 20:34 | Looking like lower lows on the chart. Sub 50p coming | letmepass | |
26/1/2021 21:25 | Massive move coming.....if not...all Technical Analysis principles which have not failed me for years are completely wrong for the very first time. Don’t get me wrong, the minor moves can be 70/30, but not the big longer timescale moves. All major methodologies are pointing to a Mkt Cap significantly North of where we are today. | hodhasharon | |
26/1/2021 21:18 | Second day running someone's building!// | bobaxe1 | |
26/1/2021 19:08 | A rapid rise from here is inevitable considering the options spelled out already. We have noted big buys throughout the past few days/weeks including Directors. The BOD's back is against the wall and they have to deliver this time, no more ifs/buts. They have to pull out all the stops. I believe they will before end of Q1. Fingers crossed and staying positive as they have a great product for the present and future market. Could there be an offer from the IV market leader??? | frrinvest | |
26/1/2021 18:01 | 450,000 buys after hours | t0pgrader | |
26/1/2021 14:58 | Sng has already paid out twice, but I know what you mean. Be nice if this paid out too !// | bobaxe1 | |
26/1/2021 14:24 | If/when SNG pays out I will be buying back in if the price remains sub £1. GLA. | adman50 | |
26/1/2021 12:30 | hxxps://www.ii.co.uk Thanks t0pgrader for highlighting | growthinvestor2001 | |
25/1/2021 19:04 | 500,000 shares bt 4-5pm today vs insignificant sells | t0pgrader | |
25/1/2021 18:43 | 25th Jan 2021 interactive investor feature an article on STX entitled "Insider: Shield Therapeutics duo bet on US success" | t0pgrader | |
25/1/2021 10:41 | Finding difficult to buy. With my broker I don't usually have any probs buying but this time no. Looks like shares are being hoovered up. | frrinvest | |
24/1/2021 01:17 | Read the words... what I said was it depends on which way the rerating goes. If someone chooses to infer that was downwards then that's your choice... I didn't. I am a holder and have been since mid 2018 and remain so - having known a couple of people with IBD related anaemia who very clearly benefitted from the product. Thanks to the good work the company has previously done from a development persepctive as well as in the IR/PR area, I have been able to adjust my position over that time when there have been opportunities to take profit, but fortunately continue to be significantly above my average in price and hope the company gets itself sorted and the share price responds accordingly as I continue to think Feraccru is an excellent product. However I simply think the current BOD and management are just not up to the job, which I believe has been well evidenced over the last few months, so have recently posted a few comments to hopefully engender some thoughtful debate around that. C'est la vie. Get the gist? | innittowinit | |
23/1/2021 13:14 | @ Onceaday There's nothing to back so what are you expecting - a declaration of support for a financing that hasn't even been approved in principle let alone structured? Another daft comment BTW three more recent examples of bio/life-science co's whose share prices are materially ahead of their recent placing prices: AGL share price now 75p vs placing @45p DEST share price now 115p vs placing @65p RUA share price now 175p vs placing @120p | t0pgrader | |
23/1/2021 13:09 | My only recent experience of an AIM fundraise was ReNeuron. The shares dropped from above £1 a few weeks before to the open offer price of 70p. They have now recovered but I assume a similar scenario. I don't understand why W. Health LP who own 47% of the stock are not being mentioned as backers. | onceaday | |
23/1/2021 12:55 | @ EKCS no one wants to bother reading responses to innit's daft comments like his suggestion the reason why STX is engaging with lenders is because they cant fund the raise through equity when the opposite is the case to minimise shareholder dilution or his musing that there's going to be a rerating but it could be downwards; there's not a soul on this board or any other presenting an argument for a derating from this level. Get the gist? | t0pgrader | |
22/1/2021 16:06 | Being the mug I am I've had a little top up, only because the Director has, he knows better than me. Gla | bobaxe1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions